{{articledata.title}}

Investing.com -- Hims Hers Health Inc (NYSE:HIMS) shares jumped 5.8% in premarket trading Tuesday after the company announced plans to acquire European digital health platform ZAVA, signaling a bold step in its international ambitions. The all-cash deal, slated to close in the second half of 2025, will bring the U.S.-based telehealth firm into Germany, France, Ireland, and further solidify its presence in the U.K.

The acquisition is part of a broader effort to position Hims&Hers as a global digital health leader, extending its personalized care services well beyond its base of 2.4 million U.S. customers. The addition of ZAVA’s 1.3 million active customers represents a 50% surge in total user base, unlocking new revenue pathways across key European markets.

ZAVA conducted nearly 2.3 million digital consultations in 2024 alone across the U.K., Germany, France, and Ireland, demonstrating the platform’s operational leverage and local market expertise. Hims&Hers plans to create a branded footprint in each of these countries, leveraging ZAVA’s clinical infrastructure while integrating its own technology and consumer experience.

“The demand for simpler, more personalized healthcare is universal,” said Andrew Dudum, founder and CEO of Hims&Hers. “By leveraging ZAVA’s established European presence, cutting-edge technology, and deep customer understanding, we’re poised to fundamentally transform access to care for millions across Europe.”

ZAVA’s co-founder and CEO David Meinertz welcomed the transaction, highlighting their complementary strengths. “By joining forces with Hims&Hers, we can put that standard within reach of millions more people across Europe,” he said.

The integration will allow Hims to offer care across dermatology, weight loss, sexual health, and mental health, with access to local-language providers in Germany, France, and the U.K. The company said it would share more details over the coming months and expects the deal to be accretive by 2026.

“We’re excited to take this moment to really accelerate both the European expansion, but also use this platform as an accelerant as we move into more markets,” Dudum added in an interview with CNBC. With growing demand for direct-to-consumer personalized health services, Hims&Hers’ expansion may mark the start of a new phase for global telemedicine.

Shares rose 5.8% in premarket trading, reflecting investor optimism around the company’s accelerating global ambitions and the sizable boost in its customer footprint.

This content was originally published on http://Investing.com